Eric Laille

1.6k total citations
38 papers, 1.1k citations indexed

About

Eric Laille is a scholar working on Hematology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Eric Laille has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 17 papers in Molecular Biology and 10 papers in Infectious Diseases. Recurrent topics in Eric Laille's work include Acute Myeloid Leukemia Research (27 papers), Histone Deacetylase Inhibitors Research (13 papers) and HIV/AIDS drug development and treatment (10 papers). Eric Laille is often cited by papers focused on Acute Myeloid Leukemia Research (27 papers), Histone Deacetylase Inhibitors Research (13 papers) and HIV/AIDS drug development and treatment (10 papers). Eric Laille collaborates with scholars based in United States, Switzerland and United Kingdom. Eric Laille's co-authors include Barry Skikne, Guillermo Garcia‐Manero, Steven D. Gore, Kyle J. MacBeth, Christopher R. Cogle, Tao Shi, Hagop M. Kantarjian, Joel Hetzer, Robert E. Martell and Bart L. Scott and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Eric Laille

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Laille United States	16	703	631	208	165	104	38	1.1k
Charlotte Guldborg Nyvold Denmark	18	364 0.5×	529 0.8×	167 0.8×	185 1.1×	288 2.8×	73	982
Inge Høgh Dufva Denmark	12	402 0.6×	843 1.3×	264 1.3×	309 1.9×	265 2.5×	22	1.1k
Shuchi Agrawal India	11	536 0.8×	348 0.6×	121 0.6×	79 0.5×	60 0.6×	21	775
Giridharan Ramsingh United States	15	328 0.5×	316 0.5×	130 0.6×	103 0.6×	70 0.7×	52	691
G. Corneo Italy	16	443 0.6×	384 0.6×	153 0.7×	208 1.3×	108 1.0×	43	936
Chang‐Ki Min South Korea	16	271 0.4×	430 0.7×	251 1.2×	83 0.5×	67 0.6×	43	698
Cosimo Cumbo Italy	15	254 0.4×	279 0.4×	77 0.4×	162 1.0×	100 1.0×	45	566
Giuseppina Tota Italy	16	261 0.4×	269 0.4×	77 0.4×	153 0.9×	96 0.9×	41	571
James M. Bogenberger United States	14	405 0.6×	202 0.3×	181 0.9×	67 0.4×	40 0.4×	26	573
Toshiya Yokozawa Japan	8	281 0.4×	222 0.4×	100 0.5×	107 0.6×	108 1.0×	17	528

Countries citing papers authored by Eric Laille

Since Specialization

Citations

This map shows the geographic impact of Eric Laille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Laille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Laille more than expected).

Fields of papers citing papers by Eric Laille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Laille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Laille. The network helps show where Eric Laille may publish in the future.

Co-authorship network of co-authors of Eric Laille

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Laille. A scholar is included among the top collaborators of Eric Laille based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Laille. Eric Laille is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eijkelenburg, Natasha K. A. van, Henrik Hasle, Charlotte M. Niemeyer, et al.. (2023). Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015). Pediatric Drugs. 25(6). 719–728. 3 indexed citations

Gaudy, Allison, et al.. (2023). Population Pharmacokinetics of Oral Azacitidine, and Exposure–Response Analysis in Acute Myeloid Leukemia. Clinical Pharmacology & Therapeutics. 114(4). 845–852. 4 indexed citations

Babiker, Hani M., Mohammed Milhem, Joseph Aisner, et al.. (2020). Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemotherapy and Pharmacology. 85(3). 621–626. 7 indexed citations

Hoff, Daniel D. Von, Drew Rasco, Elisabeth I. Heath, et al.. (2018). Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research. 24(17). 4072–4080. 27 indexed citations

Lima, Marcos de, Betül Oran, Richard E. Champlin, et al.. (2018). CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 24(10). 2017–2024. 115 indexed citations

Maruyama, Dai, Kensei Tobinai, Michinori Ogura, et al.. (2017). Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. International Journal of Hematology. 106(5). 655–665. 24 indexed citations

Chou, Wen‐Chien, Su‐Peng Yeh, Liang‐Tsai Hsiao, et al.. (2017). Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher‐risk myelodysplastic syndromes. Asia-Pacific Journal of Clinical Oncology. 13(5). e430–e439. 5 indexed citations

Du, Xin, Yue‐Yun Lai, Ting Liu, et al.. (2017). Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study. Asia-Pacific Journal of Clinical Oncology. 14(3). 270–278. 9 indexed citations

Laille, Eric, Tao Shi, Guillermo Garcia‐Manero, et al.. (2015). Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS ONE. 10(8). e0135520–e0135520. 48 indexed citations

10.

Garcia‐Manero, Guillermo, Steven D. Gore, Suman Kambhampati, et al.. (2015). Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 30(4). 889–896. 86 indexed citations

11.

Laille, Eric, Manish R. Patel, Suzanne F. Jones, et al.. (2015). Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer. The Journal of Clinical Pharmacology. 55(12). 1378–1385. 7 indexed citations

12.

William, Basem M., Marcos de Lima, Betül Oran, et al.. (2014). CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Blood. 124(21). 990–990. 4 indexed citations

13.

Laille, Eric, Michael R. Savona, Bart L. Scott, et al.. (2013). Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. The Journal of Clinical Pharmacology. 54(6). 630–639. 26 indexed citations

14.

Laille, Eric, Sanjay Goel, Alain C. Mita, et al.. (2013). A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 34(5). 440–451. 16 indexed citations

15.

Garcia‐Manero, Guillermo, Steven D. Gore, Christopher R. Cogle, et al.. (2011). Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Journal of Clinical Oncology. 29(18). 2521–2527. 193 indexed citations

16.

Gore, Steven D., Christopher R. Cogle, Barry Skikne, et al.. (2011). Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). Blood. 118(21). 1546–1546. 4 indexed citations

17.

Chen, Yong, Lisa Liu, Eric Laille, Gondi Kumar, & Sekhar Surapaneni. (2010). In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer Chemotherapy and Pharmacology. 65(5). 995–1000. 9 indexed citations

18.

Garcia‐Manero, Guillermo, Steven D. Gore, Christopher R. Cogle, et al.. (2010). Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. Blood. 116(21). 603–603. 7 indexed citations

19.

MacBeth, Kyle J., Eric Laille, Yuhong Ning, et al.. (2009). A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.. Blood. 114(22). 1772–1772. 2 indexed citations

20.

Jacobson, Elliott R., et al.. (2003). Plasma concentrations of praziquantel after oral administration of single and multiple doses in loggerhead sea turtles ( Caretta caretta ). American Journal of Veterinary Research. 64(3). 304–309. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact